Does Rallies show 13F holders for SKYE?

Yes. Rallies tracks hedge fund and 13F ownership data for SKYE, including fund names, share counts, latest tracked quarter, and position changes when available.

Is SKYE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SKYE. It does not provide personalized investment advice.

SKYE (Skye Bioscience, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Skye Bioscience, Inc. Common Stock (SKYE) is a publicly traded Healthcare sector company. As of May 20, 2026, SKYE trades at $0.74 with a market cap of $27.33M and a P/E ratio of -0.52. SKYE moved +0.00% today. Year to date, SKYE is -17.42%; over the trailing twelve months it is -66.27%. Its 52-week range spans $0.57 to $5.96. Analyst consensus is buy with an average price target of $9.50. Rallies surfaces SKYE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns SKYE stock?

Hedge funds tracked by Rallies that own SKYE include Exoduspoint Capital. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Skye Bioscience, Inc. Common Stock.

SKYE Key Metrics

Key financial metrics for SKYE
Metric	Value
Price	$0.74
Market Cap	$27.33M
P/E Ratio	-0.52
EPS	$-1.41
Dividend Yield	0.00%
52-Week High	$5.96
52-Week Low	$0.57
Volume	48.16K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-55.92M
Gross Margin	0.00%

Top Hedge Funds Holding SKYE

Exoduspoint Capital holds 24.55K shares of SKYE, changed +0.00% as of Sep 30, 2024.

Latest SKYE News

Skye Bioscience Advances to 600mg Nimacimab Cohort After Safe 400mg Dosing — May 20, 2026
Skye to Showcase Nimacimab Phase 2a Add-On Data with Semaglutide on April 16 — Apr 7, 2026
Skye Bioscience Doses First Patient in 400 mg and 600 mg IV Nimacimab Study Expansion — Apr 2, 2026
Skye Bioscience Sees 22.3% Weight Loss, Plans Higher Doses After 200 mg Underexposure — Mar 12, 2026
Skye Bioscience Initiates 400mg/600mg IV Expansion Study, Reports 22.3% Weight Loss — Mar 10, 2026

Recent SKYE Insider Trades

Schwab Andrew J. sold 163.98K (~$560.81K) on Aug 22, 2025.
Schwab Andrew J. sold 6.47K (~$22.13K) on Aug 22, 2025.
5AM Partners VII, LLC sold 163.98K (~$560.81K) on Aug 22, 2025.

SKYE Analyst Consensus

6 analysts cover SKYE: 0 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $9.50.

Common questions about SKYE

Who owns SKYE stock?: Hedge funds tracked by Rallies that own SKYE include Exoduspoint Capital. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Skye Bioscience, Inc. Common Stock.
Does Rallies show 13F holders for SKYE?: Yes. Rallies tracks hedge fund and 13F ownership data for SKYE, including fund names, share counts, latest tracked quarter, and position changes when available.
Is SKYE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SKYE. It does not provide personalized investment advice.